These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 9603013)

  • 1. Hydroxyapatite-oil composites for delivering AZT in simulated body fluid.
    Reed D; Billotte WG; Rush BJ; Odorzynski A; Kreinbrink K; Bajpai PK
    Biomed Sci Instrum; 1997; 34():59-64. PubMed ID: 9603013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous delivery of azidothymidine by hydroxyapatite or tricalcium phosphate ceramics.
    Cannon MR; Bajpai PK
    Biomed Sci Instrum; 1995; 31():159-64. PubMed ID: 7654955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term sustained delivery of 3'-azido-2',3'-dideoxythymidine in vivo by means of HA and TCP delivery devices.
    Benghuzzi H
    Biomed Sci Instrum; 2000; 36():343-8. PubMed ID: 10834256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A ceramic system for delivering interleukin-2.
    Smith SW; Billotte WG; Krane D; Sage K; Bajpai PK
    Biomed Sci Instrum; 1997; 34():65-9. PubMed ID: 9603014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parameters of protein delivery using hydroxyapatite in simulated body fluid.
    Tscholl B; Billotte WG; Reed D; Smith S; Kreinbrink K; Bajpai PK
    Biomed Sci Instrum; 1997; 34():70-5. PubMed ID: 9603015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a ceramic matrix system for continuous delivery of azidothymidine.
    Nagy EA; Bajpai PK
    Biomed Sci Instrum; 1994; 30():181-6. PubMed ID: 7948634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A hydroxyapatite system for the continuous release of coumadin an anticoagulant.
    Tarr ER; Lasserre A; Szmulowicz U; Bajpai PK
    Biomed Sci Instrum; 1997; 33():143-8. PubMed ID: 9731350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro release of azidothymidine (AZT) by ceramic drug delivery systems.
    Benghuzzi HA; Barbaro RM; Bajpai PK
    Biomed Sci Instrum; 1990; 26():151-6. PubMed ID: 2334759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and in vitro evaluation of surfactant systems for controlled release of zidovudine.
    Carvalho FC; Sarmento VH; Chiavacci LA; Barbi MS; Gremião MP
    J Pharm Sci; 2010 May; 99(5):2367-74. PubMed ID: 19967779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zidovudine induces S-phase arrest and cell cycle gene expression changes in human cells.
    Olivero OA; Tejera AM; Fernandez JJ; Taylor BJ; Das S; Divi RL; Poirier MC
    Mutagenesis; 2005 Mar; 20(2):139-46. PubMed ID: 15784690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved body distribution of 14C-labelled AZT bound to nanoparticles in rats determined by radioluminography.
    Löbenberg R; Maas J; Kreuter J
    J Drug Target; 1998; 5(3):171-9. PubMed ID: 9606007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo evaluation of the release of zidovudine and polystyrene sulfonate from a dual intravaginal bioadhesive polymeric device in the pig model.
    Ndesendo VM; Pillay V; Choonara YE; Du Toit LC; Meyer LC; Buchmann E; Kumar P; Khan RA
    J Pharm Sci; 2011 Apr; 100(4):1416-35. PubMed ID: 20960571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug combination shows benefits for AIDS patients with history of taking AZT.
    AIDS Patient Care STDS; 1996 Jun; 10(3):185-6. PubMed ID: 11361628
    [No Abstract]   [Full Text] [Related]  

  • 14. Synthesis, in vitro and in vivo release kinetics, and anti-HIV activity of a sustained-release prodrug (mPEG-AZT) of 3'-azido-3'-deoxythymidine (AZT, Zidovudine).
    Li W; Chang Y; Zhan P; Zhang N; Liu X; Pannecouque C; De Clercq E
    ChemMedChem; 2010 Nov; 5(11):1893-8. PubMed ID: 20936623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotoxicity assessed by the comet and GPA assays following in vitro exposure of human lymphoblastoid cells (H9) or perinatal exposure of mother-child pairs to AZT or AZT-3TC.
    Escobar PA; Olivero OA; Wade NA; Abrams EJ; Nesel CJ; Ness RB; Day RD; Day BW; Meng Q; O'Neill JP; Walker DM; Poirier MC; Walker VE; Bigbee WL
    Environ Mol Mutagen; 2007; 48(3-4):330-43. PubMed ID: 17358027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitochondrial toxicity in hearts of CD-1 mice following perinatal exposure to AZT, 3TC, or AZT/3TC in combination.
    Chan SS; Santos JH; Meyer JN; Mandavilli BS; Cook DL; McCash CL; Kissling GE; Nyska A; Foley JF; van Houten B; Copeland WC; Walker VE; Witt KL; Bishop JB
    Environ Mol Mutagen; 2007; 48(3-4):190-200. PubMed ID: 16395692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delavirdine combination and viral load.
    Anderson S
    AIDS Treat News; 1997 Oct; (No 281):6. PubMed ID: 11364793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-step kinetics of HIV-1 reverse transcriptase mutants responsible for virus resistance to nucleoside inhibitors zidovudine and 3-TC.
    Krebs R; Immendörfer U; Thrall SH; Wöhrl BM; Goody RS
    Biochemistry; 1997 Aug; 36(33):10292-300. PubMed ID: 9254628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P-(alkyl)-nucleoside 5'-hydrogenphosphonates as depot forms of antiviral nucleotide analogues.
    Khandazhinskaya AL; Shirokova EA; Karpenko IL; Zakirova NF; Tarussova NB; Krayevsky AA
    Nucleosides Nucleotides Nucleic Acids; 2000; 19(10-12):1795-804. PubMed ID: 11200274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained delivery of 3H-thymidine by means of ceramic capsules in rats.
    Benghuzzi HA; Barbaro RM; Bajpai PK
    Biomed Sci Instrum; 1989; 25():169-77. PubMed ID: 2742964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.